Replies to post #44857 on OncoSec Medical Inc (ONCSQ)

[chickpea598]

The new CEO was brought in to guide Oncosec in the right direction going forward. The second half of 2018 should get a little more interesting.

-Melanoma data (PISCES)
-TNBC combo trial start
-Head and Neck triplet combo trial start
-Melanoma (neo-adjuvant) combo trial start
-PIIM IND filing
-file for ATMP classification in Europe

...lots to look forward to. Merck entering onto another collaboration with Oncosec in TNBC is a good sign in my opinion even before PISCES data release. That is confidence in my book. I wouldn't be surprised if Merck is involved in every one of these additional trials to be announced upcoming.

The next generation of the immunopulse platform will be able to reach more tumor types. I have been wondering if Oncosec could go after lung cancer. Would that be an indication suitable for electroporation? That would be a huge market to go after and Merck would surely be interested in that.
NSCLC is going to be huge for Merck. A combo study with immunopulse would be huge for Oncosec.

[dangerM]

Thanks for this great summary! I couldn't have summarized it better.

[Hargrove]

This "hschlauch" post compliments his post of December 27, 2017 and supplements others made during 2018. He has provided us an ongoing study/story of what seems to be happening with ONCS' scientific/medical developments/achievements. Thanks for your expert perspective on what has transpired and what ONCS' future may very well look like. I'm all eyes and ears when I see you have posted. THANKS FOR YOUR KEEN INSIGHTS ON ONCS!